Long-Acting GLP-1/GIP Dual Agonist Shows Weekly Dosing Potential in Healthy Cats
A pharmacokinetic study in 48 healthy cats found the GLP-1/GIP dual agonist HDM7006 has a roughly 44-hour half-life, dose-proportional exposure and low immunogenicity, supporting once-weekly subcutaneous dosing for feline weight management trials. A weekly injectable weight-management drug for cats has moved…